Effective management of acute coronary thrombosis in a young woman with lupus using aggressive medical therapy.

Abstract

Systemic lupus erythematosus is a chronic inflammatory disorder that predisposes to acute coronary thrombosis. To demonstrate how the pathophysiology of lupus-mediated coronary events may be unique, we offer the case and management of a young woman with lupus who presented with acute myocardial infarction. She was initially managed with medical therapy including the standard regimen of aspirin, heparin, and clopidogrel. Despite a Thrombolysis in Myocardial Infarction risk score of only 2, she was also given eptifibatide infusion because of clinical concerns. Repeated cardiac catheterization showed marked regression of the thrombus, and coronary fractional flow reserve calculation demonstrated full recovery of coronary vasculature with this therapy. This case demonstrates effective management of life-threatening coronary thrombosis with medical therapy only in a young woman with lupus. We briefly review the pathophysiology of acute coronary thrombosis in lupus patients and distinguish this from the more common process of age-related atherosclerosis. Given the lack of evidence in this specific population, we discuss a pathophysiology-based clinical decision-making tool. Assessing clinical risk factors and using technologies such as intravascular ultrasound can help make the correct treatment decision.

• Authors: Parin J Patel, William H Matthai Jr, William J Untereker
• Journal: Cardiology (Cardiology) Vol. 118 Issue 1 Pg. 45-9 ( 2011) ISSN: 1421-9751 [Electronic] Switzerland
• PMID: 21411997 (Publication Type: Case Reports, Journal Article)
• Copyright: Copyright © 2011 S. Karger AG, Basel.

Chemical References

• Fibrinolytic Agents
• Peptides
• Platelet Aggregation Inhibitors
• Heparin
• Clopidogrel
• Eptifibatide
• Ticlopidine
• Aspirin

Topics

• Adult
• Aspirin (therapeutic use)
• Clopidogrel
• Coronary Thrombosis (drug therapy, etiology)
• Eptifibatide
• Female
• Fibrinolytic Agents (therapeutic use)
• Heparin (therapeutic use)
• Humans
• Lupus Erythematosus, Systemic (complications)
• Peptides (therapeutic use)
• Platelet Aggregation Inhibitors (therapeutic use)
• Ticlopidine (analogs & derivatives, therapeutic use)